Fundraising FoxvenBio Partners — 2024 Investments
6 investments dated 2024 · listed companies and verified rows first · show all
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalGeneral AtlanticHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMed+4 more
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Co-investorsARCH Venture PartnersForesite CapitalGeneral AtlanticHAWKTAILPureTech HealthSofinnova Ventures+4 more
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsSofinnova VenturesMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+8 more
Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.
BiotechSan Francisco, US
Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)
BoardJeff Tong(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsAlpha Wave GlobalSofinnova VenturesThird Rock VenturesForbion
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossoverThird Rock Ventures+2 more
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(Founder)inGlen McIntyre(Founder)Timothy Craven(Founder)
BoardCOREY GOODMAN(Director)inMATT HERSHENSON(Director)in
Co-investorsBEVCCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalAxial VCvenBio Global Strategic
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.